Urgent need exists for developing next-generation clinical diagnostics devices for screening individuals exposed to and/or intoxicated with biological threat agents. These devices need to be capable of rapid, sensitive, and specific diagnosis to enable effective countermeasures including therapeutic intervention. Such systems must also be easy-to-use, automated and self-contained, and preferably have a small footprint to allow use in point-of-care and point-of-incident settings. Our goal is to develop, with our commercial partners Invetech and Bio-Rad, a manufacturable and commercializable device (SpinDx) in preparation for 510(k) submission to the FDA. The device is intended for use in primary care facilities, public health labs, and military clinics overseas for detection of NIAID priority pathogens and toxins Botulinum, Anthrax, Ricin, Shiga-like toxin, and Staphyloccocus enterotoxin B (SEB) in clinical samples. Invetech will design and develop Beta prototypes ready for field-testing at Sandia and two independent laboratories using spiked human samples as well as serum and nasal swabs from intoxicated/infected mice. A test-bed version of the device has already been demonstrated with ultra-sensitive detection of a number of analytes including biotoxins (e.g., our assay for Botulinum toxin A is ~100-fold more sensitive than the gold-standard mouse bioassay). The device uses centrifugal force-driven flow to implement bead-based sandwich immunoassays and activity assays in a plastic disk, and can rapidly (<10 min) and sensitively (~ fM) detect multiple analytes using a few ?L of clinical sample. The diagnostic device, owing to its bead-based assay format, is readily adaptable to detection of other pathogens and disease markers. The device requires no off-device sample preparation and is compatible with multiple bodily fluids including whole blood, serum, saliva, and urine. We have assembled a multidisciplinary team for development, manufacturing and testing of SpinDx which includes, in addition to Sandia, Invetech and Bio-Rad, two institutions for developing animal models for intoxication/infection - United States Department of Agriculture's Western Regional Research Center (USDA-WRRC) in Albany, CA and University of Texas Medical Branch (UTMB) at Galveston, TX;and two sites for independent, blind testing of the device at UTMB Allied Health hospital lab and USDA-WRRC.

Public Health Relevance

The proposed device will be a multi-purpose medical diagnostic device that can be used to diagnose people potentially exposed to a biotoxin or pathogen. It can also be used to diagnose many other systemic diseases and conditions such as cancer and heart disease.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-FDS-M (J2))
Program Officer
Hall, Robert H
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Sandia Corp-Sandia National Laboratories
United States
Zip Code
Phaneuf, Christopher R; Mangadu, Betty; Tran, Huu M et al. (2018) Integrated LAMP and immunoassay platform for diarrheal disease detection. Biosens Bioelectron 120:93-101
Moen, Scott T; Hatcher, Christopher L; Singh, Anup K (2016) A Centrifugal Microfluidic Platform That Separates Whole Blood Samples into Multiple Removable Fractions Due to Several Discrete but Continuous Density Gradient Sections. PLoS One 11:e0153137
Phaneuf, Christopher R; Mangadu, Betty; Piccini, Matthew E et al. (2016) Rapid, Portable, Multiplexed Detection of Bacterial Pathogens Directly from Clinical Sample Matrices. Biosensors (Basel) 6:
Litvinov, Julia; Moen, Scott T; Koh, Chung-Yan et al. (2016) Centrifugal sedimentation immunoassays for multiplexed detection of enteric bacteria in ground water. Biomicrofluidics 10:014103
Koh, Chung-Yan; Schaff, Ulrich Y; Piccini, Matthew E et al. (2015) Centrifugal microfluidic platform for ultrasensitive detection of botulinum toxin. Anal Chem 87:922-8